TWI349556B - Induction of antigen specific immunologic tolerance - Google Patents

Induction of antigen specific immunologic tolerance

Info

Publication number
TWI349556B
TWI349556B TW092112346A TW92112346A TWI349556B TW I349556 B TWI349556 B TW I349556B TW 092112346 A TW092112346 A TW 092112346A TW 92112346 A TW92112346 A TW 92112346A TW I349556 B TWI349556 B TW I349556B
Authority
TW
Taiwan
Prior art keywords
induction
antigen specific
immunologic tolerance
specific immunologic
tolerance
Prior art date
Application number
TW092112346A
Other languages
English (en)
Other versions
TW200400045A (en
Inventor
D Kakkis Emil
Pssage Merry
A Tanaka Christopher
Lester Thomas
Yang Rebecca
Original Assignee
Harbor Ucla Res And Education Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Ucla Res And Education Inst filed Critical Harbor Ucla Res And Education Inst
Publication of TW200400045A publication Critical patent/TW200400045A/zh
Application granted granted Critical
Publication of TWI349556B publication Critical patent/TWI349556B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
TW092112346A 2002-05-06 2003-05-06 Induction of antigen specific immunologic tolerance TWI349556B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/141,668 US7485314B2 (en) 2002-05-06 2002-05-06 Induction of antigen specific immunologic tolerance

Publications (2)

Publication Number Publication Date
TW200400045A TW200400045A (en) 2004-01-01
TWI349556B true TWI349556B (en) 2011-10-01

Family

ID=29399718

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092112346A TWI349556B (en) 2002-05-06 2003-05-06 Induction of antigen specific immunologic tolerance

Country Status (16)

Country Link
US (3) US7485314B2 (zh)
EP (1) EP1507555B1 (zh)
JP (1) JP4933042B2 (zh)
CN (1) CN100360182C (zh)
AR (1) AR039882A1 (zh)
AU (1) AU2003228829B2 (zh)
BR (1) BR0309809A (zh)
CA (1) CA2492394A1 (zh)
ES (1) ES2401681T3 (zh)
HK (1) HK1081438A1 (zh)
IL (1) IL165016A (zh)
MX (1) MXPA04009292A (zh)
TW (1) TWI349556B (zh)
UY (1) UY27795A1 (zh)
WO (1) WO2003094840A2 (zh)
ZA (1) ZA200409787B (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003020039A1 (en) * 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
CA2484000A1 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
MX2007006640A (es) * 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
NZ560359A (en) * 2005-02-04 2009-11-27 Dow Agrosciences Llc Anti-T cell and autoantigen treatment of autoimmune disease using CD3 monoclonal antibodies and glutamic acid decarboxylase, insulin, beta cell protein or a combination thereof.
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
US20060286103A1 (en) * 2005-06-15 2006-12-21 Parag Kolhe Stable antibody formulation
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
ATE539089T1 (de) * 2007-03-21 2012-01-15 Raptor Pharmaceutical Inc Cyclische rezeptor-assoziierte-proteine (rap)- peptide
AU2009244148B2 (en) * 2008-05-07 2014-10-09 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
PT2493487T (pt) * 2009-10-27 2016-11-08 Erytech Pharma Composição para induzir uma tolerância imunitária específica
EP2632479B1 (en) * 2010-10-27 2017-06-14 Baxalta GmbH Fviii peptides for immune tolerance induction and immunodiagnostics
BR112013027508A2 (pt) 2011-04-29 2017-03-14 Selecta Biosciences Inc nanotransportadores sintéticos tolerogênicos para reduzir respostas de anticorpos
US20140135337A1 (en) * 2011-05-16 2014-05-15 Genzyme Corporation Induction of immune tolerance by using methotrexate
CN108465106B (zh) 2012-01-12 2022-05-27 普吉特海湾血液中心 降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法
WO2013150284A1 (en) * 2012-04-02 2013-10-10 University Of Bristol Tolerisation- inducing composition
CN103372214B (zh) * 2012-04-13 2017-09-29 北京艾棣维欣生物技术有限公司 治疗和/或预防ⅰ型糖尿病的药物组合物及其应用
SI3115372T1 (sl) 2012-11-27 2019-08-30 Biomarin Pharmaceutical Inc. Tarčni terapevtski fuzijski proteini lizosomalnega encima in njihove uporabe
CN111068061A (zh) * 2013-05-03 2020-04-28 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
BR112015028605A8 (pt) * 2013-05-15 2019-12-24 Univ Minnesota uso de uma composição e uso de um imunossupressor e uma composição
AU2015311706A1 (en) 2014-09-07 2017-02-02 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
AU2016349528A1 (en) 2015-11-06 2018-05-17 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
BR112018071156A2 (pt) 2016-04-15 2019-03-12 The Trustees Of The University Of Pennsylvania terapia de gene para tratar mucopolissacaridose tipo ii
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
KR20200104852A (ko) 2017-09-22 2020-09-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
CA3104797A1 (en) * 2018-06-22 2019-12-26 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
EP3897747A4 (en) 2018-12-19 2022-12-07 The Board of Trustees of the Leland Stanford Junior University BI-FUNCTIONAL MOLECULES FOR THE TARGETING OF LYSOSOMES, COMPOSITIONS AND ASSOCIATED METHODS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
DE69233507T2 (de) 1991-02-22 2009-09-10 The Walter And Eliza Hall Institute Of Medical Research, Parkville Hbgad und higad polypeptide und nukleinsäuren und deren verwendung zur diagnose und behandlung von gad autoantigen assoziierten krankheiten
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
ATE193208T1 (de) * 1992-02-10 2000-06-15 Univ Duke Verwendung synthetischer peptide zur induktion der toleranz gegen t- und b-zell epitope von autoantigenen
US5747034A (en) 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
JPH10513350A (ja) * 1995-01-31 1998-12-22 ザ ロックフェラー ユニヴァーシティ ＤＥＣ（樹状細胞及び上皮細胞、２０５ ｋＤａ）の同定、Ｃ型レクチンドメインを有するレセプター、ＤＥＣをコードする核酸、及びこれらの使用
WO1998037917A1 (en) 1997-02-28 1998-09-03 Enzo Therapeutics, Inc., A Fully Owned Subsidiary Of Enzo Biochem, Inc. Novel processes implementing selective immune down regulation (sidr)
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20050191309A1 (en) * 2002-05-06 2005-09-01 Kakkis Emil D. Induction of antigen specific immunologic tolerance

Also Published As

Publication number Publication date
BR0309809A (pt) 2007-01-09
JP2005530762A (ja) 2005-10-13
EP1507555A4 (en) 2009-07-15
US20090238818A1 (en) 2009-09-24
US20040009906A1 (en) 2004-01-15
UY27795A1 (es) 2003-11-28
MXPA04009292A (es) 2005-06-08
US20030211113A1 (en) 2003-11-13
US7883707B2 (en) 2011-02-08
ZA200409787B (en) 2006-07-26
ES2401681T3 (es) 2013-04-23
TW200400045A (en) 2004-01-01
WO2003094840A2 (en) 2003-11-20
HK1081438A1 (en) 2006-05-19
CN1652814A (zh) 2005-08-10
IL165016A0 (en) 2005-12-18
EP1507555A2 (en) 2005-02-23
EP1507555B1 (en) 2012-12-19
IL165016A (en) 2012-01-31
AU2003228829A1 (en) 2003-11-11
CA2492394A1 (en) 2003-11-20
CN100360182C (zh) 2008-01-09
WO2003094840A3 (en) 2004-03-11
JP4933042B2 (ja) 2012-05-16
AU2003228829B2 (en) 2009-05-21
US7485314B2 (en) 2009-02-03
AR039882A1 (es) 2005-03-09

Similar Documents

Publication Publication Date Title
TWI349556B (en) Induction of antigen specific immunologic tolerance
AU2003272807A8 (en) Rapid induction of mild hypothermia
HK1076223A1 (en) Induction heater
HK1081792A1 (en) Induction heating coil
GB2393760B (en) Induction system
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
EP1572131A4 (en) ANTIBODY THERAPY
DE60332821D1 (de) Induktionsheizeinrichtung
DE60331202D1 (de) Induktionsheizvorrichtung
EP1476930A4 (en) HIGH FREQUENCY CHARGER CONTROLLED BY A MICROPROCESSOR-
HK1081793A1 (en) Induction heater
GB2394255B (en) Induction device
GB0214528D0 (en) Materials and methods for induction of immune tolerance
IL156276A0 (en) Induction of tolerance
EP1568915A4 (en) FLYWHEEL
GB0324831D0 (en) Induction heating
AU2003234190A8 (en) Inhibition of immune complex formation
AU2003296325A8 (en) Induction dryer
AU2003298518A8 (en) Organosiloxanes
AU2003222975A1 (en) Induction furnace
GB0226878D0 (en) Antibodies
GB2404950B (en) Induction device
AU2003217844A8 (en) Immune regulation
AU2003248499A1 (en) Electronic induction heater
GB0211628D0 (en) Primary induction

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees